Cancer associated fibroblasts in cancer pathogenesis

Seminars in Cell and Developmental Biology

Volumn 21, Issue 1, 2010, Pages 33-39

  Franco, Omar E ^a   Shaw, Aubie K ^a   Strand, Douglas W ^a   Hayward, Simon W ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Activated fibroblasts; Cancer associated fibroblast; Myofibroblasts; Stromal epithelial interaction; Tumor heterogeneity; Tumor stroma

Indexed keywords

BREAST CANCER; CANCER THERAPY; CELL HETEROGENEITY; CLINICAL RESEARCH; COLON CANCER; HOMEOSTASIS; HUMAN; KNOWLEDGE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PROSTATE CANCER; REVIEW; STROMA; STROMA CELL; TUMOR CELL;

EID: 75849154010     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2009.10.010     Document Type: Review

References (65)

1. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9 13 (2003) 4792-4801
2. Kolf C.M., Cho E., and Tuan R.S. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther 9 1 (2007) 204
3. Tuxhorn J.A., McAlhany S.J., Dang T.D., Ayala G.E., and Rowley D.R. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62 11 (2002) 3298-3307
4. Kunz-Schughart L.A., and Knuechel R. Tumor-associated fibroblasts. Part I. Active stromal participants in tumor development and progression?. Histol Histopathol 17 2 (2002) 599-621
5. Tuxhorn J.A., Ayala G.E., and Rowley D.R. Reactive stroma in prostate cancer progression. J Urol 166 6 (2001) 2472-2483
6. Tuxhorn J.A., McAlhany S.J., Yang F., Dang T.D., and Rowley D.R. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62 21 (2002) 6021-6025
7. Yanagisawa N., Li R., Rowley D., Liu H., Kadmon D., Miles B.J., et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol 38 11 (2007) 1611-1620
8. Midwood K.S., Williams L.V., and Schwarzbauer J.E. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 36 6 (2004) 1031-1037
9. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 26 (1986) 1650-1659
10. De Wever O., Demetter P., Mareel M., and Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123 10 (2008) 2229-2238
11. Folkman J., and Kalluri R. Cancer without disease. Nature 427 6977 (2004) 787
12. Weaver V.M., and Gilbert P. Watch thy neighbor: cancer is a communal affair. J Cell Sci 117 Pt 8 (2004) 1287-1290
13. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 58 2 (2008) 71-96
14. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., and Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59 19 (1999) 5002-5011
15. Hayward S.W., Wang Y., Cao M., Hom Y.K., Zhang B., Grossfeld G.D., et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61 22 (2001) 8135-8142
16. Hill R., Song Y., Cardiff R.D., and Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 6 (2005) 1001-1011
17. Macintosh C.A., Stower M., Reid N., and Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58 1 (1998) 23-28
18. Grover A.C., Tangrea M.A., Woodson K.G., Wallis B.S., Hanson J.C., Chuaqui R.F., et al. Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med 4 (2006) 13
19. Krop I., Player A., Tablante A., Taylor-Parker M., Lahti-Domenici J., Fukuoka J., et al. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2 9 (2004) 489-494
20. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr Rev 25 2 (2004) 276-308
21. Ricciardelli C., Choong C.S., Buchanan G., Vivekanandan S., Neufing P., Stahl J., et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63 1 (2005) 19-28
22. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res 61 2 (2001) 423-427
23. Wikstrom P., Marusic J., Stattin P., and Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69 8 (2009) 799-809
24. Chung L.W., Baseman A., Assikis V., and Zhau H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173 1 (2005) 10-20
25. Bhowmick N.A., Chytil A., Plieth D., Gorska A.E., Dumont N., Shappell S., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 5659 (2004) 848-851
26. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41 6 (2005) 846-857
27. Li X., Placencio V., Iturregui J.M., Uwamariya C., Sharif-Afshar A.R., Koyama T., et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 27 56 (2008) 7118-7130
28. Lu T., Burdelya L.G., Swiatkowski S.M., Boiko A.D., Howe P.H., Stark G.R., et al. Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 101 18 (2004) 7112-7117
29. Saikali Z., Setya H., Singh G., and Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 8 (2008) 10
30. Wu J.D., Haugk K., Woodke L., Nelson P., Coleman I., and Plymate S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 99 2 (2006) 392-401
31. Knudsen B.S., and Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 91 (2004) 31-67
32. Verras M., Lee J., Xue H., Li T.H., Wang Y., and Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67 3 (2007) 967-975
33. Ye L., Lewis-Russell J.M., Sanders A.J., Kynaston H., and Jiang W.G. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol 26 2 (2008) 190-197
34. Maeda A., Nakashiro K., Hara S., Sasaki T., Miwa Y., Tanji N., et al. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 347 4 (2006) 1158-1165
35. Vindrieux D., Escobar P., and Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16 3 (2009) 663-673
36. Ao M., Franco O.E., Park D., Raman D., Williams K., and Hayward S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res 67 9 (2007) 4244-4253
37. Ao M., Williams K., Bhowmick N.A., and Hayward S.W. Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res 66 16 (2006) 8007-8016
38. Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y., and Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99 3 (2008) 539-542
39. Cheng N., Bhowmick N.A., Chytil A., Gorksa A.E., Brown K.A., Muraoka R., et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 24 32 (2005) 5053-5068
40. Cheng N., Chytil A., Shyr Y., Joly A., and Moses H.L. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 67 10 (2007) 4869-4877
41. Noel A., De Pauw-Gillet M.C., Purnell G., Nusgens B., Lapiere C.M., and Foidart J.M. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. Br J Cancer 68 5 (1993) 909-915
42. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121 3 (2005) 335-348
43. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
44. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 7162 (2007) 557-563
45. -/low subpopulation and the side population of breast cancer cells. Anticancer Res 29 6 (2009) 2147-2157
46. ten Haaf A., Bektas N., von Serenyi S., Losen I., Arweiler E.C., Hartmann A., et al. Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer 9 (2009) 298
47. Sadlonova A., Bowe D.B., Novak Z., Mukherjee S., Duncan V.E., Page G.P., et al. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron (2009). http://www.springerlink.com/content/313502j7g0282502 10.1007/s12307-008-0017-0
48. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 1 (2004) 17-32
49. Kurose K., Gilley K., Matsumoto S., Watson P.H., Zhou X.P., and Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 32 3 (2002) 355-357
50. Moinfar F., Man Y.G., Arnould L., Bratthauer G.L., Ratschek M., and Tavassoli F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60 9 (2000) 2562-2566
51. Fukino K., Shen L., Matsumoto S., Morrison C.D., Mutter G.L., and Eng C. Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res 64 20 (2004) 7231-7236
52. Qiu W., Hu M., Sridhar A., Opeskin K., Fox S., Shipitsin M., et al. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40 5 (2008) 650-655
53. Lillemoe K.D., Yeo C.J., and Cameron J.L. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 50 4 (2000) 241-268
54. Aoki H., Ohnishi H., Hama K., Shinozaki S., Kita H., Yamamoto H., et al. Existence of autocrine loop between interleukin-6 and transforming growth factor-beta1 in activated rat pancreatic stellate cells. J Cell Biochem 99 1 (2006) 221-228
55. Lohr M., Schmidt C., Ringel J., Kluth M., Muller P., Nizze H., et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61 2 (2001) 550-555
56. Kuang C., Xiao Y., Liu X., Stringfield T.M., Zhang S., Wang Z., et al. In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci USA 103 6 (2006) 1858-1863
57. Schor S.L., and Schor A.M. Clonal heterogeneity in fibroblast phenotype: implications for the control of epithelial-mesenchymal interactions. Bioessays 7 5 (1987) 200-204
58. Sugimoto H., Mundel T.M., Kieran M.W., and Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5 12 (2006) 1640-1646
59. Grum-Schwensen B., Klingelhofer J., Berg C.H., El-Naaman C., Grigorian M., Lukanidin E., et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 65 9 (2005) 3772-3780
60. Ishii G., Sangai T., Oda T., Aoyagi Y., Hasebe T., Kanomata N., et al. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 309 1 (2003) 232-240
61. Zhao H.J., and Peehl D.M. Tumor-promoting phenotype of CD90(hi) prostate cancer-associated fibroblasts. Prostate 69 9 (2009) 991-1000
62. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203 5 (2006) 1235-1247
63. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96 21 (2004) 1593-1603
64. Zeisberg E.M., Potenta S., Xie L., Zeisberg M., and Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67 21 (2007) 10123-10128
65. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13 8 (2007) 952-961